Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology

Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ARQL)

New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire October 19, 2018

ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)

Business Wire October 19, 2018

The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

Benzinga.com October 17, 2018

ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018

Business Wire October 17, 2018

The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Benzinga.com October 14, 2018

ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting

Business Wire October 4, 2018

ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

Business Wire September 24, 2018

ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018

Business Wire September 24, 2018

Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)

Business Wire September 13, 2018

ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018

Business Wire August 30, 2018

ArQule to Participate in Citi’s 13th Annual Biotech Conference on September 6, 2018

Business Wire August 30, 2018

ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018

Business Wire August 29, 2018

Analysis: Positioning to Benefit within PagSeguro Digital, ChannelAdvisor, Transocean, Arcos Dorados, Precision Drilling, and ArQule — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire August 21, 2018

ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK

Business Wire August 13, 2018

ArQule Reports Second Quarter 2018 Financial Results

Business Wire August 1, 2018

ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018

Business Wire July 18, 2018

ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Business Wire July 13, 2018

ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock

Business Wire July 11, 2018

ArQule Announces Commencement of Proposed Public Offering of Common Stock

Business Wire July 10, 2018

ArQule Added to the Russell 2000® Index

Business Wire June 25, 2018